Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Pertuzumab: development beyond breast cancer.

Barthélémy P, Leblanc J, Goldbarg V, Wendling F, Kurtz JE.

Anticancer Res. 2014 Apr;34(4):1483-91. Review.

PMID:
24692675
2.

Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.

Chung C, Lam MS.

Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735. Review.

PMID:
23988598
3.

[Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].

Sabatier R, Gonçalves A.

Bull Cancer. 2014 Jul-Aug;101(7-8):765-71. doi: 10.1684/bdc.2014.1940. French.

PMID:
25091659
4.

Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.

O'Sullivan CC, Swain SM.

Expert Opin Biol Ther. 2013 May;13(5):779-90. doi: 10.1517/14712598.2013.783007. Epub 2013 Mar 27. Review.

PMID:
23530718
5.

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.

De Mattos-Arruda L, Cortes J.

Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24. Review.

PMID:
23881722
6.

[Pertuzumab and solid tumors: perspectives].

Barthélémy P, Leblanc J, Wendling F, Wissler MP, Bergerat JP.

Bull Cancer. 2014 Dec;101(12):1114-21. doi: 10.1684/bdc.2014.2026. French.

PMID:
25532690
7.

Pertuzumab: optimizing HER2 blockade.

Metzger-Filho O, Winer EP, Krop I.

Clin Cancer Res. 2013 Oct 15;19(20):5552-6. doi: 10.1158/1078-0432.CCR-13-0518. Epub 2013 Aug 13. Review.

8.

Pertuzumab in the treatment of HER2+ breast cancer.

Jhaveri K, Esteva FJ.

J Natl Compr Canc Netw. 2014 Apr;12(4):591-8. Review.

PMID:
24717573
9.

Pertuzumab in HER2-positive breast cancer.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11. Review.

PMID:
22953713
10.

Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.

McCormack PL.

Drugs. 2013 Sep;73(13):1491-502. doi: 10.1007/s40265-013-0109-0. Review.

PMID:
23982598
11.

Pertuzumab in gastrointestinal cancer.

Oh DY, Bang YJ.

Expert Opin Biol Ther. 2016;16(2):243-53. doi: 10.1517/14712598.2016.1126578. Epub 2015 Dec 23. Review.

PMID:
26619359
12.

Pertuzumab in breast cancer: a systematic review.

Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Filipits M, Bartsch R, Dimopoulos MA, Psaltopoulou T.

Clin Breast Cancer. 2013 Oct;13(5):315-24. doi: 10.1016/j.clbc.2013.05.002. Epub 2013 Jun 27. Review.

PMID:
23810292
13.

Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.

Gerratana L, Bonotto M, Bozza C, Ongaro E, Fanotto V, Pelizzari G, Puglisi F.

Expert Opin Biol Ther. 2017 Mar;17(3):365-374. doi: 10.1080/14712598.2017.1282944. Epub 2017 Jan 30. Review.

PMID:
28092723
14.

Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.

Dawood S, Sirohi B.

Future Oncol. 2015;11(6):923-31. doi: 10.2217/fon.15.7. Review.

PMID:
25760974
15.

HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.

Kristjansdottir K, Dizon D.

Expert Opin Biol Ther. 2010 Feb;10(2):243-50. doi: 10.1517/14712590903514090. Review.

PMID:
20001562
16.
17.

Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.

Kawajiri H, Takashima T, Kashiwagi S, Noda S, Onoda N, Hirakawa K.

Expert Rev Anticancer Ther. 2015 Jan;15(1):17-26. doi: 10.1586/14737140.2015.992418. Epub 2014 Dec 12. Review.

PMID:
25494663
18.

Pertuzumab and trastuzumab: the rationale way to synergy.

Richard S, Selle F, Lotz JP, Khalil A, Gligorov J, Soares DG.

An Acad Bras Cienc. 2016;88 Suppl 1:565-77. doi: 10.1590/0001-3765201620150178. Review.

19.

Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer.

Keating GM.

Drugs. 2012 Feb 12;72(3):353-60. doi: 10.2165/11209000-000000000-00000. Review.

PMID:
22316351
20.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P.

Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.

PMID:
22153890

Supplemental Content

Support Center